Tuesday, July 11, 2017 9:10:53 AM
Recent ATOS News
- Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer • GlobeNewswire Inc. • 10/31/2024 12:15:00 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 10/22/2024 07:24:03 PM
- Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer • GlobeNewswire Inc. • 10/21/2024 12:30:00 PM
- Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit • GlobeNewswire Inc. • 10/14/2024 09:08:43 PM
- Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum • GlobeNewswire Inc. • 10/01/2024 12:30:00 PM
- Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer • GlobeNewswire Inc. • 09/10/2024 12:30:00 PM
- Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/03/2024 12:30:00 PM
- Atossa Therapeutics Granted Additional Patent Protection for Endoxifen • GlobeNewswire Inc. • 08/28/2024 12:30:00 PM
- Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer • GlobeNewswire Inc. • 08/21/2024 12:30:00 PM
- Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations • GlobeNewswire Inc. • 08/20/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2024 01:05:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 01:00:09 PM
- Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/12/2024 12:30:00 PM
- Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer • GlobeNewswire Inc. • 07/22/2024 12:30:00 PM
- Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer • GlobeNewswire Inc. • 07/02/2024 08:15:00 PM
- Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer • GlobeNewswire Inc. • 06/28/2024 12:30:00 PM
- Atossa Set to Join Russell 3000® Index Effective June 28, 2024 • GlobeNewswire Inc. • 06/17/2024 12:30:00 PM
- Atossa to Present at the Sidoti Small-Cap Investor Conference • GlobeNewswire Inc. • 06/05/2024 12:30:00 PM
- Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model • GlobeNewswire Inc. • 05/28/2024 12:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/24/2024 04:15:32 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/23/2024 01:00:04 PM
- Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial • GlobeNewswire Inc. • 05/15/2024 12:30:00 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 05/14/2024 08:46:30 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/13/2024 08:05:53 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 01:05:35 PM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM